Nektar Therapeutics (NKTR)
Market Cap | 490.56M |
Revenue (ttm) | 95.04M |
Net Income (ttm) | -454.16M |
Shares Out | 187.95M |
EPS (ttm) | -2.44 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,789,974 |
Open | 2.42 |
Previous Close | 2.46 |
Day's Range | 2.41 - 2.63 |
52-Week Range | 1.99 - 11.59 |
Beta | 0.92 |
Analysts | Sell |
Price Target | 4.50 (+72.41%) |
Earnings Date | Feb 27, 2023 |
About NKTR
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell l... [Read more]
Financial Performance
In 2021, NKTR's revenue was $101.91 million, a decrease of -33.36% compared to the previous year's $152.92 million. Losses were -$523.84 million, 17.9% more than in 2020.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for NKTR stock is "Sell." The 12-month stock price forecast is $4.5, which is an increase of 72.41% from the latest price.
News

Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA
SAN FRANCISCO , Jan. 4, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual J.P. Morgan He...

Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm
NEW YORK , Dec. 15, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) ...

Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
-- Unveils Trial Design for Nektar Phase 2/3 Study Combining NKTR-255 with CAR-T Therapies -- -- Presents First Data for NKTR-255 in Combination with Daratumumab in Patients with Relapsed/Refractory M...

Nektar Therapeutics to Host Investor & Analyst Event on December 12th
SAN FRANCISCO , Dec. 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event on Monday, December 12, 2022 at 7:30 a.m. CST. Nektar ma...

Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
NKTR-288 upregulated MHC Class I and PD-L1 expression on tumors, enhancing anti-tumor activity when combined with anti-PD-1 or anti-PD-L1 antibodies SAN FRANCISCO , Nov. 10, 2022 /PRNewswire/ -- Nekta...

Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy
-- Polymer-conjugated IL-15 (NKTR-255) induced CD8+ T cell and natural killer cell proliferation in vivo -- -- NKTR-255 enhanced the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model -...

Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates
Nektar (NKTR) reports encouraging third-quarter 2022 results. The narrower-than-expected loss is on account of lower operating expenses incurred during the quarter.

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 48.94% and 1.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics Reports Third Quarter 2022 Financial Results
SAN FRANCISCO , Nov. 3, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in marketable secu...

Nektar Therapeutics (NKTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , Oct. 25, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022, after the close of U.S.-b...

Form 8 (OPD) Nektar Therapeutics, Inc.
OPENING DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress
SAN FRANCISCO , Sept. 7, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced data presentations from two Phase 1b, proof-of-concept studies of rezpegaldesleukin (also known as LY34...

Nektar.ai exits stealth mode to plug CRM data leakages
A lot of important data gets lost along the sales pipeline because sales teams use multiple tools, including email, Zoom and WhatsApp, to talk with buyers. Nektar.

Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma
SAN FRANCISCO , Aug. 16, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society ...

Nektar's (NKTR) Q2 Earnings and Revenues Miss Estimates
Nektar (NKTR) reports dismal second-quarter 2022 results. The company's operating expenses increased due to restructuring expenses of $106.0 million incurred during the quarter.

Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 15.84% and 7.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics Reports Second Quarter 2022 Financial Results
SAN FRANCISCO , Aug. 4, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2022. Cash and investments in marketable securiti...

Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , July 26, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2022 on Thursday, August 4, 2022, after the close of U.S.-ba...

Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer
SAN FRANCISCO , July 1, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Jillian B. Thomsen to Senior Vice President (SVP) & Chief Financial Officer.

Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track
Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.

Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 31.94% and 3.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics Reports First Quarter 2022 Financial Results
SAN FRANCISCO , May 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2022. Cash and investments in marketable securitie...

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
- Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO - Renowned oncology expert Dr. John Hayslip to further...